Blog
RSS FeedPosted by Michael Wonder on 15 May 2023
ICER to assess treatment for pulmonary arterial hypertension
15 May 2023 - Report will be subject of Midwest CEPAC meeting in December 2023; draft scoping document open to ...
Posted by Michael Wonder on 24 Apr 2023
NICE collaborates with international partner agencies to streamline the confidential marking process
24 April 2023 - NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and ...
Posted by Michael Wonder on 17 Apr 2023
ICER publishes final evidence report on lecanemab for Alzheimer’s disease
17 April 2023 - Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if ...
Posted by Michael Wonder on 14 Apr 2023
Throwing the baby out with the bath water: Congress considers banning the QALY
3 April 2023 - In late March, the House Committee on Energy and Commerce advanced H.R. 485 - Protecting Health ...
Posted by Michael Wonder on 13 Apr 2023
ICER publishes evidence report on treatments for non-alcoholic steatohepatitis
13 April 2023 - Current evidence suggests that resmetirom would achieve common thresholds for cost effectiveness if priced between $39,600–$50,100 per ...
Posted by Michael Wonder on 12 Apr 2023
ICER releases draft evidence report on gene therapies for sickle cell disease
12 April 2023 - Public comment period now open until 9 May 2023; Requests to make oral comment during public ...
Posted by Michael Wonder on 15 Mar 2023
ICER publishes white paper recommending health technology assessment methods that support health equity
15 March 2023 - Informed by expert advisory group and input from external stakeholders, white paper highlights on-going need to ...
Posted by Michael Wonder on 10 Mar 2023
ICER to assess gene therapy for metachromatic leukodystrophy
9 March 2023 - Report will be subject of CTAF meeting in September 2023; draft scoping document open to public ...
Posted by Michael Wonder on 01 Mar 2023
ICER publishes evidence report on lecanemab for Alzheimer’s disease
1 March 2023 - Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health ...
Posted by Michael Wonder on 25 Feb 2023
Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment
23 February 2023 - Lifecycle considerations have always been part of health technology assessment. However, the concept of taking a fuller, ...
Posted by Michael Wonder on 21 Feb 2023
ICER publishes final evidence report on treatments for multiple sclerosis
21 February 2023 - Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit ...
Posted by Michael Wonder on 16 Feb 2023
ICER releases draft evidence report on treatments for non-alcoholic steatohepatitis
16 February 2023 - The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of resmetirom ...
Posted by Michael Wonder on 23 Jan 2023
ICER publishes final evidence report on fezolinetant for vasomotor symptoms associated with menopause
23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 22 Dec 2022
ICER releases draft evidence report on treatments for Alzheimer’s disease
22 December 2022 - Registration now open for 5 January “Early Insights” webinar. ...
Posted by Michael Wonder on 22 Dec 2022
ICER publishes final evidence report on gene therapies for haemophilia A and B
22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...